Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENA-104A16 in Advanced Solid Tumors
NCT06235541Phase 1Withdrawn
- Sponsor
- Genome & Company
- Start
- Feb 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EP0089 in solid tumor (advanced stage), sponsored by Genome & Company. Primary endpoints: Maximum Tolerated Dose at 1 year, Recommended Phase 2 Dose at 1 year and 2 more. Planned start Feb 2024; status: withdrawn.
02
Drugs
EP0089
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06235541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235541.